Portal de Periódicos da CAPES

Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities

2019; Project HOPE; Volume: 38; Issue: 1 Linguagem: Inglês

10.1377/hlthaff.2018.05162

2694-233X

Ramin Mojtabai, Christine Mauro, Melanie M. Wall, Colleen L. Barry, Mark Olfson,

Prenatal Substance Exposure Effects

Medication treatment (MT) is one of the few evidence-based strategies proposed to combat the current opioid epidemic. We examined national trends and correlates of offering MT in substance use treatment facilities in the United States. According to data from national surveys, the proportion of these facilities that offered any MT increased from 20.0 percent in 2007 to 36.1 percent in 2016—mainly the result of increases in offering buprenorphine and extended-release naltrexone. Only 6.1 percent of facilities offered all three MT medications in 2016. Facilities in states with higher opioid overdose death rates, facilities that accepted health insurance overall (and, more specifically, those that accepted Medicaid in states that opted to expand eligibility for Medicaid), and facilities in states with more comprehensive coverage of MT under their Medicaid plans had higher odds of offering MT. The findings highlight the persistent unmet need for MT nationally and the role of expansion of health insurance in the dissemination of these treatments.